title: Helicobacter pylori treatment: New perspectives using current experience.
abstract: Infection with Helicobacter pylori plays an essential role in the development of duodenal and gastric ulcers as well as in the pathobiology of gastric adenocarcinoma. Thus, successful elimination of the bacterium can reduce the risk of development of these diseases. Currently, most guidelines recommend standard triple therapy (amoxicillin+clarithromycin+proton pump inhibitor), although its efficacy is rapidly falling. Notably, traditional first-line therapy fails in almost 32% of H. pylori-carrying cases, suggesting the importance of choosing the best formulation for first-line therapy. Hence, due to the decreasing effectiveness of first-line treatment, we should be prepared to confront increasing H. pylori therapeutic defeat. Owing to increasing reports of antibiotic resistance worldwide, newer approaches and directions are necessary for managing this problematic infection. Developing and providing better anti-H. pylori strategies (probiotics, antibiotic therapy and non-traditional medicine) without using current clinical experience in treating the infection is impossible. Furthermore, development and examination of new preventive vaccines may also be a new therapeutic direction. Taken together, with regard to current experience, clinicians are highly recommended to consider all alternatives to eradicate H. pylori until a universal vaccine becomes practically available. This article aims to give an overview regarding the current status of H. pylori treatment, accordingly designing an actual overview to gain optimal strategies against this infection.
authors.affiliation: Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-111, Tehran, Iran. Electronic address: Amin.talebi@modares.ac.ir.
authors.forename: Amin
authors.initials: A
authors.lastname: Talebi Bezmin Abadi
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001428:Bacterial Vaccines / Q000302:isolation & purification; D000529:Complementary Therapies / Q000379:methods; D055808:Drug Discovery / Q000379:methods; D004359:Drug Therapy, Combination / Q000379:methods; D016481:Helicobacter Infections / Q000188:drug therapy*; D006801:Humans; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D001428:Bacterial Vaccines; D054328:Proton Pump Inhibitors
keywords: Clarithromycin; Efficacy; First-line therapy; Fluoroquinolone; Helicobacter pylori; Infection